ArticleJournal of cancer research and clinical oncology2017
Analysis of primary-miRNA-3662 and its mature form may improve detection of the lung adenocarcinoma.
Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Review
- MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2023Review
- Common Genetic Factors and Pathways in Alzheimer's Disease and Ischemic Stroke: Evidences from GWAS.Genes · 2023Review
- Functional mapping of microRNA promoters with dCas9 fused to transcriptional regulators.Frontiers in genetics · 2023Article
- MiR-205-5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer.Thoracic cancer · 2022Article
- CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.Oncogene · 2022Article
- BBOX1-AS1 Accelerates Gastric Cancer Proliferation by Sponging miR-3940-3p to Upregulate BIRC5 Expression.Digestive diseases and sciences · 2021Article
- Identification of nine microRNAs as potential biomarkers for lung adenocarcinoma.FEBS open bio · 2019Article
- MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.Cell death & disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBecause of the alarming data concerning lung cancer morbidity and mortality, investigation of new molecular markers allowing early cancer detection is desirable. In the present study, we investigated the potential role of miRNA-3662 precursor (pri-miRNA-3662) as potential novel diagnostic marker of lung adenocarcinoma (AC). MATERIALS AND
methodsExpression of miRNA-3662 and pri-miRNA-3662 was analyzed in 56 fresh-frozen tissues of non-small cell lung cancer and corresponding adjacent non-cancerous tissues using (NCT) qRT-PCR. Using receiver operating curves (ROC) analysis, the diagnostic accuracy of both studied markers for AC detection was assessed.
resultsmiRNA-3662 and its precursor were significantly overexpressed in AC compared to squamous-cell carcinoma (SCC) and NCT. Combined analysis of pri-miRNA-3662 and mature miRNA-3662 allowed to distinguish AC tissue from SCC with sensitivity of 96% and specificity of 85.7% (AUC = 0.963), and SCC from non-cancerous tissue with 92% sensitivity and 92% specificity (AUC = 0.979).
conclusionsmiRNA-3662 and its precursor are potentially involved in AC development. pri-miRNA seem to be novel interesting group of potential cancer biomarkers, because they demonstrate high diagnostic accuracy for tumor detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.